Medeze Group PCL (BKK:MEDEZE)

Market Cap	6.62B -17.3%
Revenue (ttm)	776.41M -11.2%
Net Income	196.38M -42.0%
EPS	0.18 -53.2%
Shares Out	1.07B
PE Ratio	33.72
Forward PE	25.83
Dividend	0.16 (2.58%)
Ex-Dividend Date	Apr 29, 2026

Volume	353,303
Open	6.20
Previous Close	6.20
Day's Range	6.15 - 6.25
52-Week Range	5.75 - 7.95
Beta	n/a
Analysts	Strong Buy
Price Target	8.20 (+32.26%)
Earnings Date	Aug 13, 2026

About Medeze Group PCL

Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, Philippines, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells. In addition, the company is involved in research, develops, and collects data on all types of human cellular act...

• Industry: Medical Care Facilities
• Sector: Healthcare
• Founded: 2010
• Employees: 200
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: MEDEZE

Financial Performance

In 2025, Medeze Group PCL's revenue was 776.41 million, a decrease of -11.15% compared to the previous year's 873.87 million. Earnings were 196.38 million, a decrease of -42.03%.